Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Accounts Payables: 2019-2024

Historic Accounts Payables for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $4.4 million.

  • 4D Molecular Therapeutics' Accounts Payables rose 134.71% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year increase of 134.71%. This contributed to the annual value of $4.4 million for FY2024, which is 24.78% up from last year.
  • As of FY2024, 4D Molecular Therapeutics' Accounts Payables stood at $4.4 million, which was up 24.78% from $3.5 million recorded in FY2023.
  • 4D Molecular Therapeutics' Accounts Payables' 5-year high stood at $4.8 million during FY2021, with a 5-year trough of $1.8 million in FY2020.
  • Moreover, its 3-year median value for Accounts Payables was $3.5 million (2023), whereas its average is $3.7 million.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Accounts Payables skyrocketed by 166.59% in 2021, and later tumbled by 30.27% in 2022.
  • 4D Molecular Therapeutics' Accounts Payables (Yearly) stood at $1.8 million in 2020, then soared by 166.59% to $4.8 million in 2021, then plummeted by 30.27% to $3.3 million in 2022, then grew by 5.81% to $3.5 million in 2023, then grew by 24.78% to $4.4 million in 2024.